Larry Blatt

Lawrence Blatt, Ph.D., co-founded Aligos Therapeutics, Inc. and has served as the Chief Executive Officer and a member of the board of directors since March 2018. Dr. Blatt has more than 29 years of drug research and development experience with a specific focus on biology of the immune system, infectious diseases, antiviral therapies, and relevant therapeutic interventions. Prior to Aligos, he was the Global Head of Infectious Diseases and Vaccines at Johnson & Johnson. Dr. Blatt is a serial biotech entrepreneur, who co-founded Alios BioPharma and served as its Chief Executive Officer, President and Director from inception to acquisition by Johnson & Johnson in 2014, developing therapies for viral diseases, including respiratory syncytial virus (RSV) and hepatitis C. Prior to Alios, he was Chief Scientific Officer of InterMune, Inc. (acquired by Roche in 2014). Dr. Blatt also held successive positions as Vice President of Research of SiRNA/Ribozyme Therapeutics, Vice President of Product Development at National Genetics Institute, and Product Development Team Leader, Interferons at Amgen. Lawrence achieved a Doctorate in public health administration from the University of La Verne and completed his MBA from California State University, Northridge and a Bachelor of Science degree in Microbiology from Indiana University. He is also a cofounder and chairman of the Board of Directors for Alveo Diagnostics, Alameda California. Dr. Blatt is the recipient of the Ernst & Young Entrepreneur of the Year Award in the life science category and has coauthored over 100 peer reviewed scientific publications as is listed as a coinventor on several issued and pending patent applications relating to treatment of viral diseases.